A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.
about
Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domainMUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cellsThe estrogen-dependent c-JunER protein causes a reversible loss of mammary epithelial cell polarity involving a destabilization of adherens junctionsAcetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/NeuTyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsDistinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformationARIA/HRG regulates AChR epsilon subunit gene expression at the neuromuscular synapse via activation of phosphatidylinositol 3-kinase and Ras/MAPK pathwayDiversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactionsErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancerErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancerHuman prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growthPleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase.Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf.Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calciumSynapse-specific and neuregulin-induced transcription require an ets site that binds GABPalpha/GABPbetaTyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cellsSequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland.Motogenic and morphogenic activity of epithelial receptor tyrosine kinases.Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases.The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of alpha2-integrin expression in human mammary epithelial cells.ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells.Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAILGenetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.The "A, B and C" of Her-2 DNA vaccine development.Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.
P2860
Q24551173-F838B786-0FBB-446F-A23B-47311B31CFB4Q24630950-E8174978-0642-4C27-A267-0D2B0C62D810Q24672049-C9AE07EF-D2DF-4A5B-95DF-AE57434BF508Q24683893-193424B6-58A7-498A-9B12-FC1AE0CCBA0CQ24803081-D4819FEF-FB11-4AFA-BA64-19D4508947C1Q25257668-F4FD1F97-5AC2-4A92-8735-F9BF4DCAA3C3Q28577281-43C48621-3F02-417C-9469-693D6FEF1B62Q28586713-4C0E6163-25F7-4AE6-BDF0-7AF044C3126FQ28609149-BA5A54FF-5327-4C73-BD92-ED618A4BF4BAQ28678776-625CE47B-5E05-400A-A86D-B08F31CDF01BQ33781099-CF50EF7F-BCC6-42E9-A4EC-64DBC1C227E2Q33884776-9046EFEA-1429-452F-80D3-B7AA8B39FD74Q33888963-76215B15-16E2-4F42-B8D6-9EDE7C8AE220Q33891080-88DF9E7E-B6CB-4043-9A15-B51132609468Q33967189-BA5660E4-6C0F-4830-933F-41F5C31DEBB4Q34025197-49DC8BB2-1B9C-4B4F-9D07-7846FFBC227CQ34155238-627E051F-8289-450E-87F1-4F7056E7D84DQ34436612-BB585D53-9721-4426-9D23-28DF14F6F2DFQ34551813-EDA7903F-D07E-4ED6-B2C4-680963861F0DQ34908845-F48A3C4C-71D1-438E-A3E0-589DF52054BEQ35136963-C2DC733F-F4DC-4515-AD98-8ACC4F094996Q35210241-021C126B-DA17-453A-BAFA-0C3AAED1A67CQ35846108-F4409A6E-47CC-4B70-A09F-531403063094Q36136193-559D88AC-11EA-4E80-9ED4-FE69EFD23DE4Q36236069-881422E1-D337-4575-801F-C85DD5374F05Q36236949-53B8C97E-2692-4A53-A137-18DA9DDF4C5CQ36245418-98A64D98-7845-443F-A12A-C36D8C32685BQ36326248-08179CE3-16BA-4DD9-AF33-F25ABF5CFB1EQ36334739-0E0C7163-8B6B-4CBC-BAC1-D96A894A610FQ36388955-67FC86FF-1EE7-4F90-8B6E-656111FA9C75Q36553814-D4F9F47E-85A1-403B-959D-620BB5F3C8F9Q36563516-44A24B4D-A680-452A-A0B8-5220FC01271BQ36621254-AD27C387-A62F-46CD-A197-1AEF7EBC5480Q36623838-6A7FBBA2-2A73-49B7-9A90-2A364EF9E492Q36924836-A2E71686-9234-4E1F-B4DB-C559E17674BCQ37000191-9018BD03-7AD9-40A4-9454-B34E793BF5B5Q37036281-F23A92CA-0CE6-4713-9475-564D2088EE1EQ37084243-F24033CC-5BAC-4218-BF56-22BE96D612E2Q37626805-F75A8994-74E3-495D-9E43-21797198689BQ37667783-10CF86ED-96A7-47E4-A9F6-5D44869CFD47
P2860
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1994
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A single autophosphorylation s ...... ing to the MAP kinase pathway.
@en
A single autophosphorylation s ...... ing to the MAP kinase pathway.
@nl
type
label
A single autophosphorylation s ...... ing to the MAP kinase pathway.
@en
A single autophosphorylation s ...... ing to the MAP kinase pathway.
@nl
prefLabel
A single autophosphorylation s ...... ing to the MAP kinase pathway.
@en
A single autophosphorylation s ...... ing to the MAP kinase pathway.
@nl
P2093
P2860
P1433
P1476
A single autophosphorylation s ...... ing to the MAP kinase pathway.
@en
P2093
C J Marshall
H F Paterson
R Ben-Levy
P2860
P304
P407
P577
1994-07-01T00:00:00Z